New research paves the way for safer leukaemia treatments
May 30, 2019
An international team of researchers has discovered a new and much safer way to treat a type of leukaemia that mainly affects children: T-cell acute lymphoblastic leukemia (T-ALL).
Published this week in the journal Science Translational Medicine, the research is a joint effort of Children’s Cancer Institute (Australia), VIB-KU Leuven (Belgium) and UK Dementia Research Institute (England), and is an important breakthrough in the effort to find safer ways to treat T-ALL.
“Children with T-ALL are at high risk of a poor outcome and so are given very intensive chemotherapy,” said Dr Charles de Bock, Team Leader at Children’s Cancer Institute. “Many of these children suffer long-term effects of this aggressive treatment. There is therefore a great need for new therapies that can minimise these effects.”
The breakthrough involves drugs called gamma-secretase inhibitors, which work by inhibiting the action of the enzyme ‘gamma-secretase’, an important driver in many cases of T-ALL. Previously, gamma-secretase inhibitors were unsuitable as a treatment for children because of their toxicity. However, this latest research appears to have found a way around the problem.
In an interesting twist, Alzheimer’s Disease researchers have been studying the same enzyme, as it is involved in the processing of amyloid-beta, which is strongly linked to neurodegeneration. Professor Bart De Strooper, VIB-KU Leuven Center for Brain & Disease Research and UK Dementia Research Institute, and a collaborator on the T-ALL research, explains: “Gamma-secretase is a complex that exists in very different versions. Clinical trials have been performed using non-selective inhibitors that target all versions of the complex equally. We wanted to explore whether inhibiting specific versions could fine-tune the treatment and reduce side-effects.”
Dr de Bock and fellow cancer researcher, Dr Roger Habets, VIB-KU Leuven, looked closely at gamma-secretase in cells, finding that the relative abundance of different versions of the complex was strikingly different in leukaemia cells compared with healthy cells. This led to a range of laboratory experiments which showed that targeting just one version of the complex stopped T-ALL from growing, without causing the toxicity previously associated with this class of drugs.
Dr de Bock is optimistic about the rapid translation of this research into the clinic. “Historically, these types of drugs have had very limited success due to their toxicity. Now, for the first time, we have provided proof that selectively targeting a specific version of the gamma-secretase complex is both effective and safe.”
“In the future, it may even prove possible to use this approach for other types of cancer, and potentially some other diseases,” he added.
Originally trained in Australia, de Bock spent several years at VIB-KU Leuven Center for Cancer Biology before joining Children’s Cancer Institute in January 2019 to establish his own research team. In his new role, he hopes to significantly improve understanding of how T-ALL develops, as well as continue working on new therapies.
“I’m passionate about seeing our research translate into better outcomes for people with cancer,” said de Bock. “There’s not a day in the lab that I don’t feel excited about what we are going to find out next.”
Habets et al (2019). Safe targeting of T-cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition.
Science Translational Medicine
Children’s Cancer Institute:
Phone: 0418 274 428
About Children’s Cancer Institute
Originally founded by two fathers of children with cancer in 1976, Children’s Cancer Institute is the only independent medical research institute in Australia wholly dedicated to research into the causes, prevention and cure of childhood cancer. Forty years on, our vision is to save the lives of all children with cancer and improve their long-term health, through research. The Institute has grown to now employ nearly 300 researchers, operational staff and students, and has established a national and international reputation for scientific excellence.
Our focus is on translational research, and we have an integrated team of laboratory researchers and clinician scientists who work together in partnership to discover new treatments which can be progressed from the lab bench to the beds of children on wards in our hospitals as quickly as possible. These new treatments are specifically targeting childhood cancers, so we can develop safer and more effective drugs and drug combinations that will minimise side-effects and ultimately give children with cancer the best chance of a cure with the highest possible quality of life.